---
agent_readiness:
  band: agent-aware
  dimensions:
    agent_card: false
    agent_skills: derived
    agentic_access: false
    agentic_commerce: false
    auth_clarity: bearer
    consent_identity: false
    delegated_identity: false
    dry_run_mode: false
    dynamic_client_registration: false
    error_semantics: documented
    event_surface_described: false
    idempotency: false
    mcp_server: false
    openapi_examples: partial
    protected_resource_metadata: false
    rate_limit_signal: documented
    reversibility_documented: false
    spec_presence: true
    well_known_catalog: false
  schema_version: 0.2
  score: 24.3
  scored_at: '2026-08-26'
api_count: 9
apis:
- description: The `team` custom post type — 19 published biographies at harvest time covering the executive team, board of directors, board observers and the scientific founders. The only company-specific content t
  name: Matchpoint Therapeutics Team API
  slug: matchpoint-therapeutics-team-api
- description: News archive — company press releases and third-party coverage (5 published at harvest time), spanning the October 2022 launch through the July 2025 Novartis agreement.
  name: Matchpoint Therapeutics Posts API
  slug: matchpoint-therapeutics-posts-api
- description: Corporate pages (3 published at harvest time) — the single-page homepage, the privacy policy and the terms of use. Science, Approach, Leadership and Careers are anchors within the homepage, not separa
  name: Matchpoint Therapeutics Pages API
  slug: matchpoint-therapeutics-pages-api
- description: Media library — 43 image attachments at harvest time (22 PNG, 21 JPEG).
  name: Matchpoint Therapeutics Media API
  slug: matchpoint-therapeutics-media-api
- description: Cross-content search across published posts, pages and team members. An unfiltered query returned 27 matches at harvest time.
  name: Matchpoint Therapeutics Search API
  slug: matchpoint-therapeutics-search-api
- description: Route, type, taxonomy and status discovery documents. The 222-route index at /wp-json/ is the only machine-readable contract this provider publishes and the source every artifact here was derived from
  name: Matchpoint Therapeutics Discovery API
  slug: matchpoint-therapeutics-discovery-api
- description: Categories, post tags and the team_types taxonomy. One category term exists (uncategorized); post_tag and team_types are registered but carry zero terms.
  name: Matchpoint Therapeutics Taxonomy API
  slug: matchpoint-therapeutics-taxonomy-api
- description: oEmbed 1.0 provider endpoint for matchpointtx.com URLs. The sibling /oembed/1.0/proxy route returned 401 and is excluded.
  name: Matchpoint Therapeutics oEmbed API
  slug: matchpoint-therapeutics-oembed-api
- description: Comment collection. Registered and anonymously reachable, but empty — no object on this deployment carries comments.
  name: Matchpoint Therapeutics Comments API
  slug: matchpoint-therapeutics-comments-api
artifact_total: 13
common:
- group: company
  title: ''
  type: Website
  url: https://matchpointtx.com/
- group: company
  title: ''
  type: BlogRSS
  url: https://matchpointtx.com/feed/
- group: company
  title: ''
  type: Careers
  url: https://boards.greenhouse.io/matchpointtx
- group: commercial
  title: ''
  type: PrivacyPolicy
  url: https://matchpointtx.com/privacy-policy/
- group: commercial
  title: ''
  type: TermsOfService
  url: https://matchpointtx.com/terms-conditions/
- group: company
  title: ''
  type: LinkedIn
  url: https://www.linkedin.com/company/matchpoint-therapeutics
- group: company
  title: ''
  type: Twitter
  url: https://twitter.com/matchpointtx
- group: other
  title: ''
  type: SecondaryMarket
  url: https://www.nasdaqprivatemarket.com/company/matchpoint-therapeutics/
- group: other
  title: ''
  type: SecondaryMarket
  url: https://equityzen.com/company/matchpointtherapeutics/
- group: auth
  title: ''
  type: Authentication
  url: authentication/matchpoint-therapeutics-authentication.yml
- group: design
  title: ''
  type: Conventions
  url: conventions/matchpoint-therapeutics-conventions.yml
- group: design
  title: ''
  type: Conformance
  url: conformance/matchpoint-therapeutics-conformance.yml
- group: design
  title: ''
  type: ErrorCatalog
  url: errors/matchpoint-therapeutics-problem-types.yml
- group: design
  title: ''
  type: Lifecycle
  url: lifecycle/matchpoint-therapeutics-lifecycle.yml
- group: design
  title: ''
  type: DataModel
  url: data-model/matchpoint-therapeutics-data-model.yml
- group: other
  title: ''
  type: Overlay
  url: overlays/matchpoint-therapeutics-content-overlay.yaml
- group: auth
  title: ''
  type: DomainSecurity
  url: security/matchpoint-therapeutics-domain-security.yml
- group: build
  title: ''
  type: Packages
  url: packages/matchpoint-therapeutics-packages.yml
- group: commercial
  title: ''
  type: Plans
  url: plans/matchpoint-therapeutics-plans-pricing.yml
- group: operate
  title: ''
  type: RateLimits
  url: rate-limits/matchpoint-therapeutics-rate-limits.yml
- group: agent
  title: ''
  type: LLMsTxt
  url: llms/matchpoint-therapeutics-llms.txt
- group: agent
  title: ''
  type: AgentSkill
  url: skills/_index.yml
created: '2026-08-25'
description: Matchpoint Therapeutics is a privately held biotechnology company headquartered in Watertown, Massachusetts — Cambridge at launch — that discovers precision small-molecule covalent medicines intended to transform the treatment of immune diseases and other serious illness. It was founded by covalent-chemistry, proteomics and computational-science researchers from Stanford University and Harvard Medical School, closed a $30 million seed round co-led by Atlas Venture and Access Biotechnology in November 2021, and launched publicly in October 2022 with $100 million in total financing after a $70 million Series A led by Sanofi Ventures with Vertex Ventures HC, Digitalis Ventures and Alexandria Venture Investments. Its proprietary Advanced Covalent Exploration (ACE) platform combines industry-leading chemoproteomics that detects allosteric, transient and cryptic binding pockets in native cells, machine-learning algorithms that prioritise targets and guide medicinal chemistry, and
  a continuously evolving proprietary library of covalent compounds spanning fragments through drug-like leads. In July 2025 Matchpoint entered an exclusive option and licence agreement with Novartis to develop oral covalent inhibitors against a transcription factor linked to multiple inflammatory diseases, worth up to $60 million upfront and in research funding and up to $1 billion in total potential payments. Matchpoint runs no developer program and publishes no product API, developer portal, API reference or SDK. The only machine-readable surface reachable without credentials is the WordPress REST content API behind matchpointtx.com, catalogued here.
image: https://matchpointtx.com/wp-content/uploads/2022/09/logo-matchpoint.png
layout: provider
modified: '2026-08-25'
name: Matchpoint Therapeutics
nav: Providers
network: true
overview: 'Matchpoint Therapeutics publishes 9 APIs on the [APIs.io](https://apis.io/) network, including Team API, Posts API, Pages API, and 6 more. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Discovery, and Immunology.


  Matchpoint Therapeutics'' developer surface includes authentication and 21 more developer resources.'
plans:
- name: Matchpoint Therapeutics Plans Pricing
  plan_count: 0
  slug: matchpoint-therapeutics-plans-pricing
random_paper: 6
rate_limits:
- limit_count: 0
  name: Matchpoint Therapeutics Rate Limits
  slug: matchpoint-therapeutics-rate-limits
score:
  band: thin
  composite: 28.8
  facets:
    access_clarity: 10.5
    commercial_clarity: 10.5
    contract_governance: 16.7
    contract_quality: 53.5
    developer_ergonomics: 13.7
    discoverability: 74.1
    governance: 16.7
    operational_transparency: 0.0
  provenance:
    conformance: derived
    contracts:
      callable: 100.0
      derived: 0
      marker_coverage: 0.0
      total: 9
    mcp: derived
    skills: derived
  regulatory:
    applies: true
    matched_via: tags
    regime: Health
    regime_id: health
    score: 26.3
  schema_version: 0.15.0
  scored_at: '2026-08-26'
security:
- kind: authentication
  name: Matchpoint Therapeutics Authentication
  slug: matchpoint-therapeutics-authentication
  summary_line: 0 schemes
- kind: domain-security
  name: Matchpoint Therapeutics Domain Security
  slug: matchpoint-therapeutics-domain-security
  summary_line: TLSv1.3 · DMARC
slug: matchpoint-therapeutics
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Immunology
- Covalent Chemistry
- Chemoproteomics
- Machine Learning
- Life Sciences
- content-api
website: https://matchpointtx.com/
---
